Literature DB >> 7882276

Arterial-injection chemotherapy for hepatocellular carcinoma using monodispersed poppy-seed oil microdroplets containing fine aqueous vesicles of epirubicin. Initial medical application of a membrane-emulsification technique.

S Higashi1, M Shimizu, T Nakashima, K Iwata, F Uchiyama, S Tateno, S Tamura, T Setoguchi.   

Abstract

BACKGROUND: Iodized poppy-seed oil (IPSO) has a property of depositing itself selectively in the cells of hepatocellular carcinoma (HCC). A mixture of anticancer agents and IPSO has been used widely because IPSO accumulates in tumors, but its usefulness appears limited because the anticancer agents become separated easily from IPSO and do not remain in the tumor. The authors prepared a long term inseparable, water-in-oil-in-water emulsion (W/O/W) for use in arterial-injection therapy for patients with HCC and evaluated its clinical usefulness.
METHODS: The W/O/W was prepared by a membrane-emulsification technique using a controlled pore glass with 10.6-microns pores. From December 1992 to January 1994, the W/O/W containing 8-60 mg of epirubicin was applied to the hepatic arterial-injection therapy for 21 patients with HCC to determine its antitumor and side effects.
RESULTS: After arterial infusions with W/O/W, an evident antitumor effect was observed in all 13 patients treated with W/O/W containing 40 mg or more of epirubicin with or without gelatin-sponge particles used simultaneously. In the group treated with the W/O/W containing a high dose (40 mg or more) of epirubicin, even though the gelatin-sponge particles were not used, tumor size was reduced in six of seven patients, and a 50% or greater decrease of initial alpha-fetoprotein (AFP) levels within 14 days was observed in all four patients who showed abnormal levels of serum AFP before treatment. One partial necrosis and two complete necroses of three resected tumors were confirmed histopathologically. Fever (in all patients), nausea (in two), pain in the right upper quadrant of the abdomen (in two), and slight cough (in one) were noted as minor side effects.
CONCLUSIONS: To the authors' knowledge, this is the first clinical trial using this emulsion prepared by the membrane-emulsification technique. Emulsification using a fine-pore glass membrane of equal pore size (i.e., controlled-pore glass membrane) is a new technique for preparing lipid microdroplets of equal size (monodispersed) containing aqueous fine microdroplets to form W/O/W: This technique of chemoembolization can be used to treat patients with HCC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882276     DOI: 10.1002/1097-0142(19950315)75:6<1245::aid-cncr2820750606>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Selective boron delivery by intra-arterial injection of BSH-WOW emulsion in hepatic cancer model for neutron capture therapy.

Authors:  Hironobu Yanagie; Novriana Dewi; Syushi Higashi; Ichiro Ikushima; Koji Seguchi; Ryoji Mizumachi; Yuji Murata; Yasuyuki Morishita; Atsuko Shinohara; Shoji Mikado; Nakahiro Yasuda; Mitsuteru Fujihara; Yuriko Sakurai; Kikue Mouri; Masashi Yanagawa; Tomoya Iizuka; Minoru Suzuki; Yoshinori Sakurai; Shin-Ichiro Masunaga; Hiroki Tanaka; Takehisa Matsukawa; Kazuhito Yokoyama; Takashi Fujino; Koichi Ogura; Yasumasa Nonaka; Hirotaka Sugiyama; Tetsuya Kajiyama; Sho Yui; Ryohei Nishimura; Koji Ono; Sinichi Takamoto; Jun Nakajima; Minoru Ono; Masazumi Eriguchi; Kenichiro Hasumi; Hiroyuki Takahashi
Journal:  Br J Radiol       Date:  2017-05-25       Impact factor: 3.039

2.  Ultraselective transcatheter infusion of epirubicin in water-in-oil-in-water emulsion for small hepatocellular carcinoma.

Authors:  I Ikushima; S Higashi; A Ishii; K Seguchi; Y Iryo; Y Yamashita
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

3.  Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion In Vivo.

Authors:  Hironobu Yanagie; Takashi Fujino; Masashi Yanagawa; Toshimitsu Terao; Takashi Imagawa; Mitsuteru Fujihara; Yasuyuki Morishita; Ryouji Mizumachi; Yuuji Murata; Novriana Dewi; Yuuya Ono; Ichiro Ikushima; Koji Seguchi; Masashi Nagata; Yasumasa Nonaka; Yoshitaka Furuya; Tomoyuki Hisa; Takeshi Nagasaki; Kazuhiko Arimori; Tadao Nakashima; Takumichi Sugihara; Kazuhiro Kakimi; Minoru Ono; Jun Nakajima; Masazumi Eriguchi; Shushi Higashi; Hiroyuki Takahashi
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Development of pumping emulsification device with glass membrane to form ideal lipiodol emulsion in transarterial chemoembolization.

Authors:  Toshihiro Tanaka; Tetsuya Masada; Hideyuki Nishiofuku; Yasushi Fukuoka; Takeshi Sato; Shota Tatsumoto; Nagaaki Marugami; Shushi Higashi; Kimihiko Kichikawa
Journal:  Eur Radiol       Date:  2017-12-15       Impact factor: 5.315

5.  Suppression of Tumor Growth in a Rabbit Hepatic Cancer Model by Boron Neutron Capture Therapy With Liposomal Boron Delivery Systems.

Authors:  Hironobu Yanagie; Masashi Yanagawa; Yasuyuki Morishita; Atsuko Shinohara; Novriana Dewi; Yasumasa Nonaka; Yoshitaka Furuya; Ryouji Mizumachi; Yuuji Murata; Hiroyuki Nakamura; Minoru Suzuki; Yoshinori Sakurai; Hiroki Tanaka; Shinichiro Masunaga; Koji Ono; Takumichi Sugihara; Masayuki Nashimoto; Haruo Yamauchi; Minoru Ono; Jun Nakajima; Hiroyuki Takahashi
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

6.  Tip-multi-breaking in Capillary Microfluidic Devices.

Authors:  Pingan Zhu; Tiantian Kong; Zhanxiao Kang; Xiaowei Tian; Liqiu Wang
Journal:  Sci Rep       Date:  2015-06-16       Impact factor: 4.379

7.  Preparation and Characterization of Hyaluronic Acid-Polycaprolactone Copolymer Micelles for the Drug Delivery of Radioactive Iodine-131 Labeled Lipiodol.

Authors:  Shih-Cheng Chen; Ming-Hui Yang; Tze-Wen Chung; Ting-Syuan Jhuang; Jean-Dean Yang; Ko-Chin Chen; Wan-Jou Chen; Ying-Fong Huang; Shiang-Bin Jong; Wan-Chi Tsai; Po-Chiao Lin; Yu-Chang Tyan
Journal:  Biomed Res Int       Date:  2017-01-03       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.